PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8938754-10 1996 Blocking the bradykinin binding at the B1 receptor with (Des-Arg10)-Lys-bradykinin and at the B2 receptor with D-Arg(Hyp3-Thi5.8-D-Phe7)-bradykinin, respectively, revealed that in 0.75-day-old cultures no or only a very small amount of B1 receptors are present. D-Arginine 111-116 kininogen 1 Homo sapiens 13-23 9383175-9 1997 The selective bradykinin B2-receptor antagonist D-Arg[Hyp3,Thi5, D-Tic7,Oic8]-bradykinin (Hoe 140, 0.3 micromol/l) and the cyclo-oxygenase inhibitor indomethacin (10 micromol/l) reduced the facilitatory effect of bradykinin significantly in the presence of captopril in rat and human atrium. D-Arginine 48-53 kininogen 1 Homo sapiens 14-24 9383175-9 1997 The selective bradykinin B2-receptor antagonist D-Arg[Hyp3,Thi5, D-Tic7,Oic8]-bradykinin (Hoe 140, 0.3 micromol/l) and the cyclo-oxygenase inhibitor indomethacin (10 micromol/l) reduced the facilitatory effect of bradykinin significantly in the presence of captopril in rat and human atrium. D-Arginine 48-53 kininogen 1 Homo sapiens 78-88 9383175-9 1997 The selective bradykinin B2-receptor antagonist D-Arg[Hyp3,Thi5, D-Tic7,Oic8]-bradykinin (Hoe 140, 0.3 micromol/l) and the cyclo-oxygenase inhibitor indomethacin (10 micromol/l) reduced the facilitatory effect of bradykinin significantly in the presence of captopril in rat and human atrium. D-Arginine 48-53 kininogen 1 Homo sapiens 78-88 10514289-6 1999 Substitution of the D-arginine residue by a L-lysine residue led to a 10-fold more potent bradykinin B(2) ligand [compound 22 (JMV1465) (K(i) 0.07 nM)], retaining full agonist activity on human umbilical vein. D-Arginine 20-30 kininogen 1 Homo sapiens 90-100 9650825-7 1998 A second generation of antagonists, represented by D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (HOE 140) has been found resistant to degradation, long-acting in vivo, selective and specific for the B2 receptor and potent in all species tested. D-Arginine 51-56 kininogen 1 Homo sapiens 79-89 7781710-4 1995 Application of sevoflurane following bradykinin-evoked [Ca2+]i transient diminished [Ca2+]i significantly, while bradykinin B2 receptor antagonist (D-Arg-[Hyp3, Thi5,8, D-Phe7] bradykinin) or CO2+ abolished it. D-Arginine 148-153 kininogen 1 Homo sapiens 113-123 15714750-5 1995 Preincubation of endothelial cells with bradykinin and superoxide dismutase (SOD) synergistically potentiated the increase in platelet cGMP, but was attenuated by Nomega-nitro-L-arginine, with partial restoration by L-arginine but not by D-arginine. D-Arginine 238-248 kininogen 1 Homo sapiens 40-50 7556274-6 1995 However, in the presence of exogenous Bk, kallidin, or one of the slowly degradable Bk2-receptor agonists D-Arg(Hyp3)-Bk or [Hyp3-Tyr(Me)8]-Bk they elicited potent concentration-dependent relaxations. D-Arginine 106-111 kininogen 1 Homo sapiens 84-86 7556274-6 1995 However, in the presence of exogenous Bk, kallidin, or one of the slowly degradable Bk2-receptor agonists D-Arg(Hyp3)-Bk or [Hyp3-Tyr(Me)8]-Bk they elicited potent concentration-dependent relaxations. D-Arginine 106-111 kininogen 1 Homo sapiens 84-86 7781710-4 1995 Application of sevoflurane following bradykinin-evoked [Ca2+]i transient diminished [Ca2+]i significantly, while bradykinin B2 receptor antagonist (D-Arg-[Hyp3, Thi5,8, D-Phe7] bradykinin) or CO2+ abolished it. D-Arginine 148-153 kininogen 1 Homo sapiens 113-123 3661696-8 1987 On the other hand, the bradykinin-elicited increase of Ca2+ was almost completely inhibited by a novel B2-receptor antagonist, D-Arg-[Hyp3, Thi5,8, D-Phe7]-bradykinin. D-Arginine 127-132 kininogen 1 Homo sapiens 23-33 8389325-4 1993 Moreover, in the presence of 10(-6) M D-Arg,[Hyp3,Thi5,8,D-Phe7]-bradykinin, a bradykinin B2 receptor antagonist, captopril did not inhibit but rather stimulated endothelin-1 secretion, whereas bradykinin inhibited endothelin-1 secretion, and this inhibition by bradykinin was reversed by coincubation with NG-nitro-L-arginine. D-Arginine 38-43 kininogen 1 Homo sapiens 65-75 8389325-5 1993 In addition, enhancement of nitric oxide production induced by either captopril or bradykinin was inhibited by D-Arg,[Hyp3,Thi5,8,D-Phe7]-bradykinin. D-Arginine 111-116 kininogen 1 Homo sapiens 83-93 1333254-3 1992 Furthermore, the ACE inhibitor-induced augmentation of vascular PGI2 synthesis observed in vitro was completely inhibited by the competitive bradykinin antagonist D-Arg[Hyp3,Thi5,8,D-Phe7]bradykinin suggesting that ACE inhibitors stimulate PGI2 generation by an enhancement of kinin activity. D-Arginine 163-168 kininogen 1 Homo sapiens 141-151 1333254-3 1992 Furthermore, the ACE inhibitor-induced augmentation of vascular PGI2 synthesis observed in vitro was completely inhibited by the competitive bradykinin antagonist D-Arg[Hyp3,Thi5,8,D-Phe7]bradykinin suggesting that ACE inhibitors stimulate PGI2 generation by an enhancement of kinin activity. D-Arginine 163-168 kininogen 1 Homo sapiens 188-198 7768281-2 1995 A selective and potent antagonist of the bradykinin B2 receptor has recently been discovered (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin). D-Arginine 103-108 kininogen 1 Homo sapiens 41-51 7768281-2 1995 A selective and potent antagonist of the bradykinin B2 receptor has recently been discovered (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin). D-Arginine 103-108 kininogen 1 Homo sapiens 132-142 8130263-2 1994 Bradykinin (10 nM) and interleukin 1 alpha (1 ng/ml) stimulation was blocked by the bradykinin B2 receptor antagonist, D-Arg,[Hyp3,Thi5,8, D-Phe7]bradykinin and interleukin 1 receptor antagonist (IC50 = 30 mM and 20 ng/ml, respectively), suggesting receptor mediation. D-Arginine 119-124 kininogen 1 Homo sapiens 0-10 8130263-2 1994 Bradykinin (10 nM) and interleukin 1 alpha (1 ng/ml) stimulation was blocked by the bradykinin B2 receptor antagonist, D-Arg,[Hyp3,Thi5,8, D-Phe7]bradykinin and interleukin 1 receptor antagonist (IC50 = 30 mM and 20 ng/ml, respectively), suggesting receptor mediation. D-Arginine 119-124 kininogen 1 Homo sapiens 84-94 8130263-2 1994 Bradykinin (10 nM) and interleukin 1 alpha (1 ng/ml) stimulation was blocked by the bradykinin B2 receptor antagonist, D-Arg,[Hyp3,Thi5,8, D-Phe7]bradykinin and interleukin 1 receptor antagonist (IC50 = 30 mM and 20 ng/ml, respectively), suggesting receptor mediation. D-Arginine 119-124 kininogen 1 Homo sapiens 146-156 8319757-2 1993 Injections of bradykinin into the mesenteric vascular bed induced dose-related decreases in perfusion pressure which were reduced significantly following administration of Hoe 140 (D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) (100 micrograms/kg i.v.). D-Arginine 181-186 kininogen 1 Homo sapiens 14-24 8319757-2 1993 Injections of bradykinin into the mesenteric vascular bed induced dose-related decreases in perfusion pressure which were reduced significantly following administration of Hoe 140 (D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) (100 micrograms/kg i.v.). D-Arginine 181-186 kininogen 1 Homo sapiens 210-220 1417843-3 1992 Fibroblasts respond to bradykinin by large activations of phospholipase C and increases in [Ca2+]i in a manner that was abolished by D-Arg, [Hyp3,Thi5,8,D-Phe7]-bradykinin, thus indicating the presence of B2 kinin receptors. D-Arginine 133-138 kininogen 1 Homo sapiens 23-33 1656023-5 1991 Six analogs had distinct excitatory response profile and the rank order of potency of these agonists according to pD2 (shown in parentheses) was D-Arg-[Hyp3Thi5,8D-Phe7]-BK (6.49 +/- 0.19) greater than [Thi5,8D-Phe7]-BK (5.61 +/- 0.26) greater than Lys-Lys-[Hyp3-Thi5,8D-Phe7]-BK (5.45 +/- 0.14) greater than BK (5.16 +/- 0.20) greater than [des-Arg9]-BK (4.95 +/- 0.08) greater than [D-Phe7]-BK (4.73 +/- 0.10). D-Arginine 145-150 kininogen 1 Homo sapiens 170-172 1656023-5 1991 Six analogs had distinct excitatory response profile and the rank order of potency of these agonists according to pD2 (shown in parentheses) was D-Arg-[Hyp3Thi5,8D-Phe7]-BK (6.49 +/- 0.19) greater than [Thi5,8D-Phe7]-BK (5.61 +/- 0.26) greater than Lys-Lys-[Hyp3-Thi5,8D-Phe7]-BK (5.45 +/- 0.14) greater than BK (5.16 +/- 0.20) greater than [des-Arg9]-BK (4.95 +/- 0.08) greater than [D-Phe7]-BK (4.73 +/- 0.10). D-Arginine 145-150 kininogen 1 Homo sapiens 217-219 1656023-5 1991 Six analogs had distinct excitatory response profile and the rank order of potency of these agonists according to pD2 (shown in parentheses) was D-Arg-[Hyp3Thi5,8D-Phe7]-BK (6.49 +/- 0.19) greater than [Thi5,8D-Phe7]-BK (5.61 +/- 0.26) greater than Lys-Lys-[Hyp3-Thi5,8D-Phe7]-BK (5.45 +/- 0.14) greater than BK (5.16 +/- 0.20) greater than [des-Arg9]-BK (4.95 +/- 0.08) greater than [D-Phe7]-BK (4.73 +/- 0.10). D-Arginine 145-150 kininogen 1 Homo sapiens 217-219 1656023-5 1991 Six analogs had distinct excitatory response profile and the rank order of potency of these agonists according to pD2 (shown in parentheses) was D-Arg-[Hyp3Thi5,8D-Phe7]-BK (6.49 +/- 0.19) greater than [Thi5,8D-Phe7]-BK (5.61 +/- 0.26) greater than Lys-Lys-[Hyp3-Thi5,8D-Phe7]-BK (5.45 +/- 0.14) greater than BK (5.16 +/- 0.20) greater than [des-Arg9]-BK (4.95 +/- 0.08) greater than [D-Phe7]-BK (4.73 +/- 0.10). D-Arginine 145-150 kininogen 1 Homo sapiens 217-219 1656023-5 1991 Six analogs had distinct excitatory response profile and the rank order of potency of these agonists according to pD2 (shown in parentheses) was D-Arg-[Hyp3Thi5,8D-Phe7]-BK (6.49 +/- 0.19) greater than [Thi5,8D-Phe7]-BK (5.61 +/- 0.26) greater than Lys-Lys-[Hyp3-Thi5,8D-Phe7]-BK (5.45 +/- 0.14) greater than BK (5.16 +/- 0.20) greater than [des-Arg9]-BK (4.95 +/- 0.08) greater than [D-Phe7]-BK (4.73 +/- 0.10). D-Arginine 145-150 kininogen 1 Homo sapiens 217-219 1656023-5 1991 Six analogs had distinct excitatory response profile and the rank order of potency of these agonists according to pD2 (shown in parentheses) was D-Arg-[Hyp3Thi5,8D-Phe7]-BK (6.49 +/- 0.19) greater than [Thi5,8D-Phe7]-BK (5.61 +/- 0.26) greater than Lys-Lys-[Hyp3-Thi5,8D-Phe7]-BK (5.45 +/- 0.14) greater than BK (5.16 +/- 0.20) greater than [des-Arg9]-BK (4.95 +/- 0.08) greater than [D-Phe7]-BK (4.73 +/- 0.10). D-Arginine 145-150 kininogen 1 Homo sapiens 217-219 3661696-8 1987 On the other hand, the bradykinin-elicited increase of Ca2+ was almost completely inhibited by a novel B2-receptor antagonist, D-Arg-[Hyp3, Thi5,8, D-Phe7]-bradykinin. D-Arginine 127-132 kininogen 1 Homo sapiens 156-166 17699739-0 2007 B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. D-Arginine 8-13 kininogen 1 Homo sapiens 36-46 17699739-0 2007 B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. D-Arginine 8-13 kininogen 1 Homo sapiens 92-102 12227494-4 2002 The [Ca2+]i response of BK (100 nM) was inhibited by 10 micro M of the BKB2 antagonist, D-Arg-[Hyp3, Thi5,8, D-Phe7]-BK, and HIST (1 mM) was completely inhibited by 100 nM of the H1 antagonist, (+)-chlorpheniramine, in the presence and absence of extracellular Ca2+ (1.5 mM). D-Arginine 88-93 kininogen 1 Homo sapiens 24-26 29240458-9 2018 These targeted DEMs were significantly enriched in D-Arginine and D-ornithine metabolism and glycerolipid metabolism of Kyoto Encyclopedia of Genes and Genomes pathways, and enriched in bradykinin receptor activity and haptoglobin binding of gene ontology biological processes. D-Arginine 51-61 kininogen 1 Homo sapiens 186-196 18565624-1 2008 B-9430 (d-Arg-[Hyp3, Igl5, D-Igl7, Oic8]-bradykinin), where Hyp is trans-4-hydroxyproline, Igl is alpha-(2-indanyl)glycine and Oic is (3as, 7as)-octahydroindol-2-yl-carbonyl is a high affinity bradykinin B2 receptor antagonist with effects extended to the B1 receptors at high concentrations. D-Arginine 8-13 kininogen 1 Homo sapiens 41-51